Pharmacokinetics and the drug-target residence time concept

Drug Discovery Today

Volumn 18, Issue 15-16, 2013, Pages 697-707

  Dahl, Göran ^a   Akerud, Tomas ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ALISKIREN; AMLODIPINE; AMPRENAVIR; APREPITANT; ATAZANAVIR; BOCEPREVIR; CANDESARTAN; CILUPREVIR; DESLORATADINE; EFAVIRENZ; ELVITEGRAVIR; GRANISETRON; INDINAVIR; IPRATROPIUM BROMIDE; LAPATINIB; LOPINAVIR; METHOTREXATE; NELFINAVIR; OSELTAMIVIR; PHENYTOIN; RALTEGRAVIR; RITONAVIR; SAXAGLIPTIN; TELAPREVIR; TELMISARTAN; TIOTROPIUM BROMIDE; TRICLOSAN; UNINDEXED DRUG; VERAPAMIL;

BINDING KINETICS; CHEMICAL MODEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TARGETING; HUMAN; MEAN RESIDENCE TIME; PHARMACOKINETICS; PLASMA HALF LIFE; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEINS;

EID: 84881171375     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.02.010     Document Type: Review

References (60)

1. R.A. Copeland Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discov. 5 2006 730 739 (Pubitemid 44323700)
2. D.C. Swinney Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3 2004 801 808 (Pubitemid 39242832)
3. R. Zhang, and F. Monsma The importance of drug-target residence time Curr. Opin. Drug Discov. Dev. 12 2009 488 496
4. R.A. Copeland The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety Expert Opin. Drug Discov. 5 2010 305 310
5. H. Lu, and P.J. Tonge Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14 2010 467 474
6. R.A. Copeland Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3 2011 1491 1501
7. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492 (Pubitemid 351711169)
8. G. Vauquelin, and S.J. Charlton Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 2010 488 508
9. G. Vauquelin Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time Expert Opin. Drug Discov. 5 2010 927 941
10. M. Holz, and A. Fahr Compartment modeling Adv. Drug Deliv. Rev. 48 2001 249 264 (Pubitemid 32434406)
11. G. Vauquelin, and I. Van Liefde Slow antagonist dissociation and long-lasting in vivo receptor protection Trends Pharmacol. Sci. 27 2006 356 359
12. H.J. Motulsky, and L.C. Mahan The kinetics of competitive radioligand binding predicted by the law of mass action Mol. Pharmacol. 25 1984 1 9 (Pubitemid 14223246)
13. R.J. Darling, and P.A. Brault Kinetic exclusion assay technology: characterization of molecular interactions Assay Drug Dev. Technol. 2 2004 647 657 (Pubitemid 40309424)
14. Y. Fang Label-free cell-based assays with optical biosensors in drug discovery Assay Drug Dev. Technol. 4 2006 583 595 (Pubitemid 46017402)
15. L. Neumann HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature Methods Enzymol. 493 2011 299 320
16. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies, 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 91 2002 129 156 (Pubitemid 34074473)
17. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies, II. Generic physiologically based pharmacokinetic models of drug disposition J. Pharm. Sci. 91 2002 1358 1370 (Pubitemid 34651198)
18. P.L. Toutain, and A. Bousquet-Melou Plasma terminal half-life J. Vet. Pharmacol. Ther. 27 2004 427 439 (Pubitemid 39665130)
19. L.M. Berezhkovskiy Determination of mean residence time of drug in plasma and the influence of the initial drug elimination and distribution on the calculation of pharmacokinetic parameters J. Pharm. Sci. 98 2009 748 762
20. B. Disse Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease Life Sci. 64 1999 457 464 (Pubitemid 29066693)
21. S. Kapur, and P. Seeman Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action J. Psychiatry Neurosci. 25 2000 161 166 (Pubitemid 30233553)
22. G. Tresadern Molecular properties affecting fast dissociation from the D2 receptor Bioorg. Med. Chem. 19 2011 2231 2241
23. A.S. Perelson HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time Science 271 1996 1582 1586 (Pubitemid 26097216)
24. A.U. Neumann Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
25. S. Legewie Recurrent design patterns in the feedback regulation of the mammalian signalling network Mol. Syst. Biol. 4 2008 190
26. B.B. Aldridge Physicochemical modelling of cell signalling pathways Nat. Cell Biol. 8 2006 1195 1203 (Pubitemid 44660581)
27. J. Singh The resurgence of covalent drugs Nat. Rev. Drug Discov. 10 2011 307 317
28. A. Tamrazi Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate Mol. Endocrinol. 16 2002 2706 2719 (Pubitemid 36020652)
29. B.A. Ploeger Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling Drug Metab. Pharmacokinet. 24 2009 3 15
30. M. Elg The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis Thromb. Haemost. 78 1997 1286 1292 (Pubitemid 27464600)
31. A. Fura Role of pharmacologically active metabolites in drug discovery and development Drug Discov. Today 11 2006 133 142 (Pubitemid 43375964)
32. S. Shugarts, and L.Z. Benet The role of transporters in the pharmacokinetics of orally administered drugs Pharm. Res. 26 2009 2039 2054
33. P. Casarosa Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J. Pharmacol. Exp. Ther. 330 2009 660 668
34. J.M. Jansat Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects Int. J. Clin. Pharmacol. Ther. 47 2009 460 468
35. T. Gossas Aliskiren displays long-lasting interactions with human renin Naunyn Schmiedebergs Arch. Pharmacol. 385 2012 219 224
36. S. Vaidyanathan Clinical pharmacokinetics and pharmacodynamics of aliskiren Clin. Pharmacokinet. 47 2008 515 531 (Pubitemid 351969826)
37. R.S. Obach Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds Drug Metab. Dispos. 36 2008 1385 1405 (Pubitemid 351929323)
38. C.F. Shuman Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data J. Med. Chem. 47 2004 5953 5961 (Pubitemid 39507337)
39. B.M. Sadler, and D.S. Stein Clinical pharmacology and pharmacokinetics of amprenavir Ann. Pharmacother. 36 2002 102 118 (Pubitemid 34052954)
40. C. Le Tiec Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir Clin. Pharmacokinet. 44 2005 1035 1050 (Pubitemid 41356390)
41. O.M. Klibanov Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C Pharmacotherapy 32 2012 173 190
42. R. Hubner Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers J. Hum. Hypertens. 11 Suppl. 2 1997 S19 S25
43. M. Geitmann Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors J. Mol. Recognit. 24 2011 60 70
44. D. Lamarre An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189 (Pubitemid 37442587)
45. P.P. Major Clinical pharmacology of deoxycoformycin Blood 58 1981 91 96 (Pubitemid 11064465)
46. M. Affrime A pharmacokinetic profile of desloratadine in healthy adults, including elderly Clin. Pharmacokinet. 41 Suppl. 1 2002 13 19 (Pubitemid 34804168)
47. C. Csajka Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin. Pharmacol. Ther. 73 2003 20 30 (Pubitemid 36158483)
48. S. Ramanathan Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir Clin. Pharmacokinet. 50 2011 229 244
49. B.S. Kappelhoff Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients Br. J. Clin. Pharmacol. 60 2005 276 286 (Pubitemid 41224135)
50. N.P. van Erp Clinical pharmacokinetics of tyrosine kinase inhibitors Cancer Treat. Rev. 35 2009 692 706
51. R.S. Cvetkovic, and K.L. Goa Lopinavir/ritonavir: a review of its use in the management of HIV infection Drugs 63 2003 769 802 (Pubitemid 36432083)
52. X. Panhard Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART Br. J. Clin. Pharmacol. 60 2005 390 403 (Pubitemid 41428470)
53. R. Gugler Phenytoin: pharmacokinetics and bioavailability Clin. Pharmacol. Ther. 19 1976 135 142
54. M. Iwamoto Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects Clin. Pharmacol. Ther. 83 2008 293 299
55. A. Hsu Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin. Pharmacokinet. 35 1998 275 291 (Pubitemid 28491214)
56. J.J. Neumiller, and R.K. Campbell Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus Am. J. Health Syst. Pharm. 67 2010 1515 1525
57. I. Yamada Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection J. Viral Hepat. 19 2012 e112 e119
58. D. Price Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients Expert Opin. Drug Metab. Toxicol. 5 2009 417 424
59. G. Sandborgh-Englund Pharmacokinetics of triclosan following oral ingestion in humans J. Toxicol. Environ. Health A 69 2006 1861 1873 (Pubitemid 44352854)
60. 14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Drug Metab. Dispos. 37 2009 536 544